Table 4 Kaplan–Meier survival analysis for the epigenetic signature in these three sets
From: Epigenetic signature predicts overall survival clear cell renal cell carcinoma
Variable | Training set (n = 213) | Testing set (n = 106) | Entire set (n = 319) | |||
|---|---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
All | 13.0 (8.0–21.2) | < 0.0001 | 4.1 (2.2–7.7) | < 0.0001 | 7.2 (4.9–10.6) | < 0.0001 |
Age (years) | ||||||
≥ 65 | 7.6 (3.7–15.8) | < 0.0001 | 2.9 (1.2–7.4) | 0.0178 | 4.5 (2.5–8.0) | < 0.0001 |
< 65 | 16.8 (8.6–32.8) | < 0.0001 | 5.4 (2.3–12.7) | 0.0002 | 9.6 (5.7–16.3) | < 0.0001 |
Gender | ||||||
Female | 15.7 (6.8–36.4) | < 0.0001 | 4.5 (1.2–16.6) | 0.0071 | 9.3 (4.6–18.8) | < 0.0001 |
Male | 12.1 (6.5–22.5) | < 0.0001 | 4.0 (1.9–8.2) | 0.0005 | 6.4 (4.0–11.2) | < 0.0001 |
Pathological stage | ||||||
Stage I/II | 10.4 (4.3–25.3) | < 0.0001 | – | 0.4414 | 5.2 (2.4–11.4) | < 0.0001 |
Stage III/IV | 10.7 (5.9–19.3) | < 0.0001 | 2.5 (1.2–5.2) | 0.0258 | 5.3 (3.3–8.3) | < 0.0001 |
Histologic grade | ||||||
Grade I/II | 10.6 (3.0–38.1) | < 0.0001 | – | 0.5311 | 5.1 (1.9–13.8) | < 0.0001 |
Grade III/IV | 10.1 (5.8–17.8) | < 0.0001 | 3.9 (2.0–7.9) | 0.0007 | 6.1 (3.9–6.4) | < 0.0001 |
Lymph node metastasis | ||||||
Positive | – | 0.0048 | – | 0.5651 | 3.3 (1.4–7.4) | 0.0222 |
Negative | 12.2 (7.1–21.0) | < 0.0001 | 5.5 (2.5–12.3) | < 0.0001 | 8.6 (5.5–13.5) | < 0.0001 |